Gilead Sciences Inc. closed 10.06% short of its 52-week high of $119.96, which the company achieved on March 10th.

NORTHAMPTON, MA / ACCESS Newswire / March 25, 2025 / HIV infection and lung cancer have little in common from a disease ...

It’s been a long minute since we’ve spent time in the hellscape of Gilead with The Handmaid’s Tale. Season five wrapped up in ...

The head of the U.N. AIDS agency says Donald Trump should enable the American company Gilead to roll out its prevention drug ...

Gilead Sciences sees strong growth in HIV & oncology with BIKTARVY & TRODELVY. Learn about upcoming drugs & market potential ...

The Health and Human Services Department is considering cuts to HIV prevention funding, according to The Wall Street Journal.

Gilead is set to launch a Phase III trial of its once-yearly lenacapavir pre-exposure prophylaxis (PrEP) for human ...

The series, based on the Margaret Atwood novel of the same name, is set 15 years after the events of “The Handmaid’s Tale.” ...

Hulu‘s The Handmaid’s Tale sequel series The Testaments has added Mattea Conforti (The Many Saints of Newark, Power) to its ...

RBC Capital analyst Brian Abrahams maintained a Hold rating on Gilead Sciences (GILD – Research Report) today and set a price target of $90.00.

Rowan Blanchard has reportedly joined the cast of Hulu's adaptation of author Margaret Atwood's "Handmaid's Tale" sequel, The ...